ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 409,57
-0,15%
Dow Jones
43 852,70
-0,14%
DAX
20 405,92
-0,11%
Brent Oil
74,25
1,42%
Bitcoin
101 556,71
1,50%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. NGM Biopharmaceuticals Inc (NGM)

  7. NGM Biopharmaceuticals Inc (NGM) Actualités

NGM

NGM Biopharmaceuticals (NGM)

NGM Biopharmaceuticals Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:NGM
DateHeureSourceTitreSymboleSociété
05/04/202415h19GlobeNewswire Inc.NGM Bio Announces Closing of Tender OfferNASDAQ:NGMNGM Biopharmaceuticals Inc
19/03/202422h30GlobeNewswire Inc.NGM Bio to Present Two Posters Highlighting Clinical Data from the Ongoing Phase 1/2 Clinical Trial of NGM707, a Dual ILT2/ILT4 Antagonist Antibody Product Candidate, at AACR 2024 Annual MeetingNASDAQ:NGMNGM Biopharmaceuticals Inc
11/03/202421h15Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:NGMNGM Biopharmaceuticals Inc
11/03/202421h13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:NGMNGM Biopharmaceuticals Inc
11/03/202421h05GlobeNewswire Inc.NGM Bio Provides Recent Business Highlights and Reports Fourth Quarter and Full Year 2023 Financial ResultsNASDAQ:NGMNGM Biopharmaceuticals Inc
08/03/202423h32Edgar (US Regulatory)Form SC 13E3 - Going private transaction by certain issuersNASDAQ:NGMNGM Biopharmaceuticals Inc
08/03/202423h21Edgar (US Regulatory)Form SC 14D9 - Solicitation, recommendation statementsNASDAQ:NGMNGM Biopharmaceuticals Inc
26/02/202423h11Edgar (US Regulatory)Form SC14D9C - Written communication relating to third party tender offerNASDAQ:NGMNGM Biopharmaceuticals Inc
26/02/202415h03GlobeNewswire Inc.NGM Bio Has Entered into a Definitive Agreement and Plan of Merger with Certain Affiliates of The Column Group, LPNASDAQ:NGMNGM Biopharmaceuticals Inc
20/02/202422h01GlobeNewswire Inc.NGM Bio to Participate in the Cowen 44th Annual Health Care ConferenceNASDAQ:NGMNGM Biopharmaceuticals Inc
15/02/202400h12Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:NGMNGM Biopharmaceuticals Inc
19/01/202400h03Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
17/01/202422h47GlobeNewswire Inc.NGM Bio to Participate in the B. Riley Securities 4th Annual Oncology ConferenceNASDAQ:NGMNGM Biopharmaceuticals Inc
09/01/202414h00GlobeNewswire Inc.NGM Bio Announces New Clinical Data from Ongoing Trial of NGM707 in Advanced Solid Tumors and Outlines Evolved Strategy for Aldafermin and NGM120 to Focus on Rare Conditions with Significant Unmet NeedNASDAQ:NGMNGM Biopharmaceuticals Inc
13/11/202315h45GlobeNewswire Inc.NGM Bio Presents Positive Phase 2b Results from the ALPINE 4 Trial of Aldafermin in Patients with Compensated Cirrhosis (F4) Due to NASH at AASLD The Liver Meeting®NASDAQ:NGMNGM Biopharmaceuticals Inc
09/11/202300h13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:NGMNGM Biopharmaceuticals Inc
07/11/202322h05GlobeNewswire Inc.NGM Bio to Participate in Upcoming Investor ConferencesNASDAQ:NGMNGM Biopharmaceuticals Inc
02/11/202321h12Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:NGMNGM Biopharmaceuticals Inc
02/11/202321h01GlobeNewswire Inc.NGM Bio Reports Third Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:NGMNGM Biopharmaceuticals Inc
11/10/202322h05GlobeNewswire Inc.NGM Bio Announces Oral Plenary Presentation of Data from Phase 2b ALPINE 4 Trial of Aldafermin in Compensated Cirrhosis (F4) Due to NASH at Upcoming AASLD The Liver Meeting®NASDAQ:NGMNGM Biopharmaceuticals Inc
27/09/202314h30PR Newswire (US)Alexandria Real Estate Equities, Inc.'s One-of-a-Kind, Essential Labspace Platform Empowers the Integration and Enhancement of Biological Discoveries Enabled by AI to Widen the Opportunities for and Accelerate the Development of Novel MedicinesNASDAQ:NGMNGM Biopharmaceuticals Inc
11/09/202322h01Edgar (US Regulatory)Form 8-K/A - Current report: [Amend]NASDAQ:NGMNGM Biopharmaceuticals Inc
07/08/202306h15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:NGMNGM Biopharmaceuticals Inc
04/08/202323h01Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:NGMNGM Biopharmaceuticals Inc
04/08/202322h01Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:NGMNGM Biopharmaceuticals Inc
03/08/202322h01GlobeNewswire Inc.NGM Bio Reports Second Quarter 2023 Financial Results and Provides Business HighlightsNASDAQ:NGMNGM Biopharmaceuticals Inc
08/06/202312h31Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3)NASDAQ:NGMNGM Biopharmaceuticals Inc
08/06/202312h07Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:NGMNGM Biopharmaceuticals Inc
12/05/202323h55Edgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:NGMNGM Biopharmaceuticals Inc
08/05/202322h05GlobeNewswire Inc.NGM Bio Announces Presentation of Data from Phase 2 Investigator-Sponsored Trial of Aldafermin for the Treatment of Patients with Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) and Bile Acid Malabsorption (BAM) at Digestive Disease Week 2023NASDAQ:NGMNGM Biopharmaceuticals Inc
 Showing the most relevant articles for your search:NASDAQ:NGM

Dernières Valeurs Consultées

NYSE
YOKU
BIT
UC7F68
Unicredit Bank
BIT
UIJ413
Unicredit Bank
BIT
P1KUG5
BNP Paribas Issuance
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés